Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib

A retrospective cohort study

Jianwei Tang, MDa, Rui Zhao, MD,b, Xiaobao Zheng, MDa, Liangliang Xu, MDa, Yong Wang, MD,b, Lei Feng, MDa, Shengsheng Ren, MDa, Peng Wang, MDa, Ming Zhang, MDA*, Mingqing Xu, MDa*,

Abstract

In 2014, Joensuu and colleagues devised the first recurrence risk score (RRS) to identify the risk factors for gastrointestinal stromal tumor (GIST) recurrence. However, there are scarce data available on RRS effectiveness and efficiency. Therefore, we retrospectively analyzed clinical data to validate Joensuu’s RRS in patients treated with adjuvant imatinib.

In this retrospective cohort study, data were collected from patients with GIST who were treated with adjuvant imatinib between December 2005 and May 2017 in the West China Hospital. The study consisted of 137 patients, after application of inclusion and exclusion criteria. Recurrence-free survival (RFS) was the primary end point.

The RFSs for 137 patients were divided into 3 groups: low (n = 46), medium (n = 48), and high (n = 43). The RFSs of the 3 groups were significantly different (P < .001). In patients who received adjuvant imatinib for <36 months, the RFS difference was also significant (P < .001), and the result was similar in patients treated with adjuvant imatinib for ≥36 months (P = .03). The area under the curve of the RRS was 0.84 [95% confidence interval] 0.76–0.92, P < .001, suggesting that the RRS method could accurately assess recurrence risks for patients with GIST who were treated with adjuvant imatinib.

It is appropriate to apply the RRS method to assess recurrence risks for patients with GIST who were treated with adjuvant imatinib. A longer adjuvant imatinib duration is recommended for high-risk patients with GIST. It is also important to identify a more effective treatment for patients who are resistant to imatinib.

Abbreviations: AUC = area under the curve, CI = confidence interval, GIST = gastrointestinal stromal tumor, HR = hazard ratio, IQR = interquartile range, RFS = recurrence-free survival, ROC = receiver-operating characteristics, RRS = recurrence risk score.

Keywords: adjuvant imatinib, GIST, high-risk, retrospective analysis, risk factors

1. Introduction

Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal soft tissue malignancy. Approximately 80% of GISTs contain an activating mutation in the KIT oncogene, whereas 5% to 10% have a mutation in the gene encoding PDGFRα. Complete surgical resection is the standard treatment for localized, primary GISTs, but approximately 40% to 50% of patients experience recurrence. Imatinib can reduce the relapse of patients with GIST who undergo complete resection, and this has been confirmed by many studies. Imatinib is recommended as the standard first-line treatment for GIST, and ≥3 years of adjuvant imatinib is the recommended treatment for high-risk patients with GIST who undergo complete resection, based on the Scandinavian Sarcoma Group SSGXVIII/AIO randomized phase III trial (NCT00116935). Therefore, many guidelines suggest that 3 years of adjuvant imatinib for high-risk patients with GIST after complete resection effectively decreases recurrence. Many high-risk patients with GIST have received adjuvant imatinib for 3 years after surgery, and some patients have even been treated for >3 years. However, some patients experience disease recurrences soon after stopping imatinib, and scarce data are available about the recurrence risk factors in high-risk patients treated with adjuvant imatinib.
In 2014, Joensuu and colleagues first identified the GIST recurrence risk factors in this setting and devised the recurrence risk score (RRS), based on the SSGXVIII/AIO and ACOSOG Z9001 trials.\textsuperscript{18} RRSs can be used to guide follow-ups, counseling, and treatments for high-risk patients with GIST who are treated with adjuvant imatinib. Currently, relevant RRS research is sparse and lacks results from prospective studies. Therefore, we retrospectively analyzed clinical data to validate the Joensuu’s RRS in patients treated with adjuvant imatinib.

2. Methods

2.1. Patients

In this retrospective cohort study, data were collected from patients with GIST who were treated with adjuvant imatinib between December 2005 and May 2017 in the West China Hospital. Our study included 1021 patients, all of whom were confirmed by immunohistochemistry. The inclusion criteria met the requirements of the RRS and were as follows: patients were KIT (CD117) positive by immunohistochemistry; underwent complete resection; began adjuvant imatinib between 1 and 8 weeks after surgery; had a high-risk of recurrence that was confirmed by modified NIH criteria; which is a generally accepted risk-stratification scheme.\textsuperscript{23–25} The exclusion criteria included patients who received preoperative treatment with imatinib, did not receive imatinib therapy after surgery, and had metastatic or recurrent GIST. To validate the Joensuu’s RRS in patients treated with adjuvant imatinib, the time of GIST recurrence must be accurate. If the time was not clear, such as in patients with irregular follow-ups, the patients were not included in this study. For patients who died, the time of recurrence was included, but the time of death was not included. Finally, the study enrolled 137 patients who fulfilled the inclusion and exclusion criteria.

2.2. Follow-up

Professional researchers postoperatively followed-up the patients, and the follow-ups included CT or MRI of the abdomen and pelvis and CT of the chest or chest x-ray. A CT or MRI scan was performed at 3-month intervals for first 2 years and subsequently at 6-month intervals. Blood cell counts and chemistries were performed at 1- to 3-month intervals during the treatment period, and subsequently at 6-month intervals after stopping imatinib. All patients were closely followed, and the follow-up periods ranged from 5 months to 8.3 years, with a mean duration of 45.6 months. The primary end point was recurrence-free survival (RFS).

2.3. Ethics statement

The study protocol was approved by the ethics committee of the West China Hospital, Sichuan University. Written informed consent was obtained from the patients and families of the patients, even though the study was retrospective in nature. Patient records/information was anonymized and deidentified before analysis, and the methods were performed in accordance with approved guidelines.

2.4. Statistical analyses

All statistical analyses were performed using SPSS version 20.0 (for window, IBM). We used the \( \chi^2 \) test to compare categorical data and the \( t \) test or ANOVA to compare continuous data. The survival data were compared using the Kaplan–Meier method, and the log-rank test model was used to detect differences in the survival curves of the various subgroups. The Cox proportional hazards model (hazard ratios [HRs]) was used to analyze the prognostic factors associated with RFS and relationships among various factors. Receiver-operating characteristics (ROC) curves were constructed to assess sensitivity, specificity, and respective areas under the curves (AUCs), with 95% confidence intervals (CIs). All \( P \) values were 2-sided, and \( P \) values of <.05 were considered statistically significant.

3. Results

3.1. Characteristics

The baseline characteristics of the patients and tumors are shown in Table 1. The most frequent location of the primary tumor was the stomach (\( n=68, 49.6\% \)), followed by the small intestine (\( n=40, 29.2\% \)). The mean of tumor size was \( 7.6 \pm 0.4 \) cm (interquartile rang [IQR] of 5.0–10.0 cm), and the mean of tumor mitosis was 12.3 (mean) ± 5.0 (mean) per 50 HPFs. The median of the follow-up periods ranged from 5 months to 8.3 years, with a mean of 45.6 months. The primary end point was recurrence-free survival (RFS).

3.2. RFS by RRS

RRS was used to analyze the RFS for 137 patients who were treated with adjuvant imatinib and met the RRS requirements.\textsuperscript{18} The RRSs for the 137 patients were divided into 3 groups: low (RRS < 1.62, \( n=46 \)), medium (RRS = 1.62, < 2.61, \( n=48 \)), and high (RRS ≥ 2.61, \( n=43 \)). Therefore, we retrospectively analyzed clinical data to validate the Joensuu’s RRS in patients treated with adjuvant imatinib.
Joensuu and colleagues. The RFS values of the 3 groups were significantly different \( (P < .001; \text{Fig. 1}) \). The RFS of the medium group was better than that of the high group \( (\chi^2 = 6.5 \ P = .01) \), and the RFS of the low group was the best of the 3 groups \( (\chi^2 = 12.1 \ P = .001) \) (Fig. 1).

In the patients treated with adjuvant imatinib for <36 months, the differences of RFS values were also significant \( (P < .001; \text{Fig. 2}) \), and the results were similar to those of patients who were treated with adjuvant imatinib for ≥36 months \( (P = .03; \text{Fig. 3}) \).

The ROC analysis showed that RRS strongly associated with the RFS of high-risk patients with GIST who were treated with adjuvant imatinib. The AUC of RRS was 0.84 \( ([95\% \ CI] 0.76–0.92, \ P < .001; \text{Fig. 4}) \), suggesting that the RRS method can accurately assess recurrence risks in patients with GIST who are treated with adjuvant imatinib.

### 3.3. Multivariable survival analyses

In a stepwise Cox multivariable analysis of the 137 patients who were included in our study, the duration of adjuvant imatinib treatment was the only protective factor associated with RFS \( (HR [95\% \ CI], 0.92 [0.89–0.94], \ P < .001) \) (Table 2). Tumor size, tumor mitotic index, tumor rupture, and tumor site were, respectively, important independent factors that were associated with RFS \( (HR [95\% \ CI], 1.13 [1.04–1.23], \ P = .005; \text{HR [95\% \ CI], 1.01 [1.00–1.03], \ P = .002; \text{HR [95\% \ CI], 1.32 [0.65–3.55], \ P = .03; \text{HR [95\% \ CI], 2.70 [1.15–6.37], \ P = .02}) \) (Table 2).

### 4. Discussion

The incidence of GIST has been increasing\(^{[1,26,27]}\) and imatinib is recommended as the first-line targeted therapy for GIST by Clinical Practice Guidelines\(^{[28,29]}\). Surgery and adjuvant imatinib therapy after surgery are important treatments for high-risk GIST. However, there is scarce data about the recurrence risks of patients with GIST who are treated with adjuvant imatinib. The following interesting discoveries were identified by our investigation.
The RRS values demonstrate that recurrences in high-risk patients with GIST who were treated with adjuvant imatinib were different (Figs. 1 and 3). For example, the outcomes of high-risk patients with gastric GISTs were more favorable than those of high-risk patients with nongastric GISTs, although the risk stratifications were same. This suggests that the patient outcomes were greatly different among those with the same degree of risk. Based on previous studies and our retrospective data, adjuvant imatinib therapy for 3 years is insufficient for all high-risk patients with GIST, and longer durations of adjuvant imatinib therapy might decrease recurrence for some high-risk patients with high RRSs. Therefore, when high-risk patients with GIST finish adjuvant imatinib therapy after 36 months, we should use the RRS to reassess the risk of GIST recurrence, and a longer-term follow-up investigation is warranted. Despite these caveats, it appears that our findings could contribute to the follow-up and individualized treatments of patients with GIST.

5. Conclusions

The RRS method is appropriate for assessing recurrence risks in patients with GIST who are treated with adjuvant imatinib. In summary, based on the RRS, longer durations of adjuvant imatinib are necessary for high-risk patients with GIST. It is also important to develop more effective and new treatments for high-risk patients with GIST who are resistant to imatinib and did not undergo long durations of adjuvant imatinib therapy.

Acknowledgments

We thank the support staff at the West China Hospital, Sichuan University.

Author contributions

Conceptualization: Jianwei Tang, Ming Zhang.
Data curation: Jianwei Tang, Rui Zhao, Xiaobo Zheng, Liangliang Xu, Yong Wang, Lei Feng, Shengsheng Ren, Peng Wang.
Formal analysis: Jianwei Tang.
Funding acquisition: Ming Zhang.
Project administration: Mingqing Xu.
Software: Xiaobo Zheng.
Writing – original draft: Jianwei Tang.
Writing – review and editing: Ming Zhang, Mingqing Xu.

References

[1] Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007;7:7.
[2] Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013;382:973–83.
[3] Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumours. Clin Cancer Res 2012;18:1769–76.
[4] Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumours. Am J Pathol 2000;156:791–5.
[5] Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–9.
[6] Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science 2003;299:708–10.
[7] Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 2012;9:351–8.
[8] Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–6.
[9] Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002;347:472–80.
[10] Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumours expressing KIT. J Clin Oncol 2008;26:620–5.
[11] Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34.
[12] Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase. J Clin Oncol 2008;26:626–32.
[13] DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097–104.
[14] Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumours. Mol Cancer Ther 2003;2:699–709.
[15] Heinrich MC, Blanke CD, Drucker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-molecular mechanisms of action of Gleevec in gastrointestinal stromal tumours. Mol Cancer Ther 2003;2:699–709.
[16] Casali PG, Le Cesne A, Velasco AP, et al. Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumours (GIST) treated with adjuvant imatinib (IM): the EORTC/AGITG/FSG/GEIS/SG randomized controlled phase III trial. J Clin Oncol 2013;31:
[17] Joensuu H, Eriksson M, Hall KS, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumour—a randomized trial. JAMA 2012;307:1265–72.
[18] Joensuu H, Eriksson M, Hall KS, et al. Risk factors for gastrointestinal stromal tumour recurrence in patients treated with adjuvant imatinib. Cancer 2014;120:2325–33.
[19] Koo DH, Ryu MH, Kim KM, et al. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat 2016;48:1155–66.
[20] Poveda A, del Muro XG, Lopez-Guerrero JA, et al. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol 2014;74:883–98.
[21] Poveda A, Martinez V, Serrano C, et al. SEOM clinical guideline for gastrointestinal sarcomas (GIST) (2016). Clin Trans Oncol 2016;18:1221–8.
[22] von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016 Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016;14:758–86.
[23] Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol 2002;33:459–65.
[24] Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39:1411–9.
[25] Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour—the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011;37:890–6.
[26] Nilsson B, Bunning P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumours: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 2005;103:821–9.
[27] Sandvik OM, Soreide K, Kvalov JT, et al. Epidemiology of gastrointestinal stromal tumours: single-institution experience and clinical presentation over three decades. Cancer Epidemiol 2011;35:515–20.
[28] Barnes T, Reinke D. Practical management of imatinib in gastrointestinal stromal tumors. Clin J Oncol Nurs 2011;15:533–45.
[29] Italiano A, Cioffi A, Maki RG, et al. Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. J Clin Oncol 2011;29:1.
[30] Lin JX, Chen QF, Zheng CH, et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up. J Cancer Res Clin Oncol 2017;143:727–34.
[31] Cunanan MJ, Balachandran VP, Chi P, et al. Chronic imatinib (>3-years) therapy after complete resection of primary, high-risk gastrointestinal stromal tumor (GIST) is associated with low recurrence. J Am Coll Surg 2016;223:844–144.
[32] Heinrich MC, Corless CL, Blank et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumours. J Clin Oncol 2006;24:4764–74.
[33] Debuc-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRa mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689–95.
[34] Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294–9.
[35] Antonescu CR, Besmer P, Guo TH, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182–90.
[36] Debuc-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumours and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;132:270–9.
[37] Parfitt JR, Streutker CJ, Riddell RH, et al. Gastrointestinal stromal tumours: a contemporary review. Pathol Res Pract 2006;202:837–47.
[38] Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360–7.
[39] Younus J, Verma S, Franek J, et al. Sunitinib malate for gastrointestinal stromal tumour recurrence in patients treated with adjuvant imatinib (IM): the EORTC/AGITG/FSG/GEIS/ISG (IFS) in patients with localized gastrointestinal stromal tumors (GIST). Cancer 2004;40:689–95.
[40] von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2016 Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016;14:758–86.